Neogen Corp (NEOG) bonds
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)
Close on Nov 17, 2026Market cap $2.38BP/E –Yield –
Debt
Borrowings on the balance sheet, Aug 31, 2026
Total debt
$1.55B
$780.00M due within a year
Net debt
$1.38B
After $172.00M of cash
Implied interest rate
1.94%
FY2026 interest ÷ average debt
Interest coverage
-0.9×
FY2026 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at May 31, 2025
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Neogen's 10-Q for the period ended Aug 31, 2026
Neogen's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| Revolving Credit Facility | – | $48.50M |
See a number that looks wrong?